SH3D19

Across TCGA pan-cancer cohorts, SH3D19 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of SH3D19’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where SH3D19 RNA is repressed in tumor relative to normal tissue. In most cancer types SH3D19 is over-expressed in tumor, although a few such as BLCA and LUSC show the opposite, repressed pattern.

BLCA, LUSC, and KICH are the cancer types where SH3D19 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SH3D19 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Male	All	−1.658	.001	8	view →
LUSC	Female	All	−1.219	<.001	8	view →
KICH	Female	All	−1.595	<.001	7	view →
LUAD	Female	III,IV	−0.925	<.001	7	view →
UCEC	All	III,IV	−1.998	<.001	6	view →
BRCA	All	III,IV	−1.579	<.001	6	view →
CHOL	All	All	+0.660	.004	5	view →
THCA	All	II,III,IV	−0.465	.003	5	view →
COAD	Female	All	−0.751	.003	4	view →
READ	All	All	−0.928	.001	2	view →
STAD	Female	All	−0.645	.044	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

SH3D19–BLCA

Open the BLCA breakdown →